Limitations, agreements, and source contact

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation · Source last updated 2019-03-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

restrictive Agreement

false

limitations And Caveats

description

Study terminated due to lack of funding. No analysis, patient data on this protocol due to the fact that only four patients was able to be accrued.

point Of Contact

email

zalkadh@emory.edu

organization

Barbara Ann Karmanos Cancer Institute

phone

404-778-5984

title

Zaid Al-Kadhimi, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice